Making progress in treating multiple myeloma with total therapies: issue of complete remission and more

Article metrics

  • A Corrigendum to this article was published on 13 August 2008

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2


  1. 1

    Bergsagel L . A kinder, gentler way: control of the proliferative tumour compartment, not cosmetic complete response, should be the goal of myeloma therapy. 2008; (In press).

  2. 2

    Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008; e-pub ahead of print 17 January 2008.

  3. 3

    Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

  4. 4

    Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685.

  5. 5

    Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356.

  6. 6

    Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950–956.

  7. 7

    Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

  8. 8

    Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164.

  9. 9

    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

  10. 10

    Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, Van Rhee F et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2007; In press.

  11. 11

    Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393–399.

  12. 12

    Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692–1700.

  13. 13

    Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.

  14. 14

    Haessler J, JD SJ, Zhan F, Crowley J, Epstein J, van Rhee F et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073–7079.

  15. 15

    van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827–832.

  16. 16

    Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr JD et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121–1128.

  17. 17

    Barlogie B, Tricot G . Complete response in myeloma: a Trojan horse? Blood 2006; 108: 2134.

Download references


This work was supported by a program project grant from the National Institutes of Health (CA55819). We thank our medical support staff for their tireless efforts. We appreciate the trust and confidence of our patients and their referring physicians.

Author information

Correspondence to B Barlogie.

Rights and permissions

Reprints and Permissions

About this article

Further reading